Loading cancer entity…
Loading cancer entity…
Clinical trials
10,628 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (1,642)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT03616782 | Ixazomib Maintenance in Patients With Newly Diagnosed Mantle Cell Lymphoma(MCL) | unknown | Phase 2 | 98 | Ho Sup LeeOTHER | 1 | Oct 6, 2023 | clinicaltrials |
| NCT03697356 | R-VRD Followed by Lenalidomide Maintenance in Patients With Waldenstrom's Macroglobulinemia(Ballondor) | unknown | Phase 2 | 54 | Kosin University Gospel HospitalOTHER | 1 | Oct 6, 2023 | clinicaltrials |
| NCT05329792 | L19IL2/L19TNF in Skin Cancer Patients(IntriNSiC) | unknown | Phase 2 | 70 | Philogen S.p.A.INDUSTRY | 3 | Oct 6, 2023 | clinicaltrials |
| NCT06067581 | the Safety and Efficacy of SENL103 Autologous T Cell Injection | unknown | Early Phase 1 | 20 | Hebei Senlang Biotechnology Inc., Ltd.INDUSTRY | 1 | Oct 5, 2023 | clinicaltrials |
| NCT05378971 | Clinical Research of Pomalidomide Maintenance Therapy for Primary Multiple Myeloma | unknown | N/A | 15 | LanZhou UniversityOTHER | 1 | Oct 4, 2023 | clinicaltrials |
| NCT04712864 | Study of CD4-Targeted Chimeric Antigen Receptor T-Cells (CD4- CAR-T) in Subjects With Relapsed or Refractory T-Cell Lymphoma | unknown | Phase 1 | 50 | Legend Biotech USA IncINDUSTRY | 1 | Oct 3, 2023 | clinicaltrials |
| NCT06060080 | Efficacy and Safety of PEG-rhG-CSF Injection for Neutrophil Reconstitution Following AHSCT in Lymphoma/Multiple Myeloma | unknown | N/A | 7 | Yao LiuOTHER | 1 | Sep 29, 2023 | clinicaltrials |
| NCT04693676 | A Study of C-CAR039 Treatment in Subjects With r/r NHL Subjects Non-Hodgkin's Lymphoma | unknown | Phase 1 | 17 | First Affiliated Hospital of Zhejiang UniversityOTHER | 1 | Sep 28, 2023 | clinicaltrials |
| NCT06049381 | Tumor Microenvironment Mechanism of LY007 for r/r B-NHL and the Exploration of Novel CAR-T Translational Research | unknown | — | 22 | Ruijin HospitalOTHER | 0 | Sep 22, 2023 | clinicaltrials |
| NCT04187118 | Quality of Life in Lymphoma Patients One Year Post-chemotherapy(QUALIPSO-L) | unknown | — | 600 | University Hospital, ToulouseOTHER | 1 | Sep 21, 2023 | clinicaltrials |
| NCT05781386 | A Phase I Trial of SIM1811-03 in Subjects With Advanced Tumors | unknown | Phase 1 | 255 | Jiangsu Simcere Biologics Co., LtdINDUSTRY | 1 | Sep 21, 2023 | clinicaltrials |
| NCT05979948 | A Phase 2 Clinical Trial to Evaluate Zanubrutinib Combined With BR (Bendamustine/Rituximab) Regimen in Subjects With Newly-diagnosed Waldenström's Macroglobulinemia(CZ-WM01) | unknown | Phase 2 | 60 | Shanghai Changzheng HospitalOTHER | 1 | Sep 14, 2023 | clinicaltrials |
| NCT06037239 | Phase I/II Study of Linperlisib Plus Chidamide for R/R Cutaneous T-cell Lymphoma: a Prospective, Single-center Study | unknown | Phase 1 / Phase 2 | 53 | Peking Union Medical College HospitalOTHER | 1 | Sep 14, 2023 | clinicaltrials |
| NCT06026995 | Clinical Study on PEG-rhG-CSF in Mobilizing Autologous Hematopoietic Stem Cells | unknown | Phase 4 | 174 | Chongqing University Cancer HospitalOTHER | 1 | Sep 7, 2023 | clinicaltrials |
| NCT03759093 | CURATE.AI Optimized Modulation for Multiple Myeloma | unknown | Phase 2 / Phase 3 | 20 | National University Hospital, SingaporeOTHER | 1 | Sep 6, 2023 | clinicaltrials |
| NCT05174338 | Cardiac Amyloidosis Registry Study(CARS) | unknown | — | 5,000 | Cedars-Sinai Medical CenterOTHER | 2 | Sep 6, 2023 | clinicaltrials |
| NCT05296772 | Phase 1 First-in-human Study of JS014 | unknown | Phase 1 | 60 | Anwita BiosciencesINDUSTRY | 1 | Sep 6, 2023 | clinicaltrials |
| NCT05896007 | Zanubrutinib Combined With Rituximab and Chemotherapy for Newly-Diagnosed PCNSLBCL Patients Intolerant to HSCT | unknown | Phase 2 | 29 | Ruijin HospitalOTHER | 1 | Sep 5, 2023 | clinicaltrials |
| NCT05926427 | Orelabrutinib Combined With Rituximab and Chemotherapy for Relapsed/Refractory B-Cell Lymphoma Patients With Central Nervous System Involvement | unknown | Phase 2 | 25 | Ruijin HospitalOTHER | 1 | Sep 5, 2023 | clinicaltrials |
| NCT05963347 | Go-CHOP as the Frontline Therapy for PTCL | unknown | Phase 2 | 45 | Henan Cancer HospitalOTHER_GOV | 1 | Sep 1, 2023 | clinicaltrials |
| NCT06015464 | An Ambispective Cohort Study of Orelabrutinib in Combination With Standard Treatment Regimen for Untreated DLBCL | unknown | — | 81 | The First Affiliated Hospital with Nanjing Medical UniversityOTHER | 1 | Aug 29, 2023 | clinicaltrials |
| NCT03490084 | Impacts on Health Outcomes and Resources Utilization of Hospital-at-home for Elderly Patients With Multiple Myeloma(PAMM-HAD1) | unknown | — | 300 | Assistance Publique - Hôpitaux de ParisOTHER | 1 | Aug 28, 2023 | clinicaltrials |
| NCT04309981 | Clinical Trial Using Humanized CART Directed Against BCMA (ARI0002h) in Patients With Relapsed/Refractory Multiple Myeloma to Proteasome Inhibitors, Immunomodulators and Anti-CD38 Antibody. | unknown | Phase 1 / Phase 2 | 73 | Sara V. LatorreOTHER | 1 | Aug 28, 2023 | clinicaltrials |
| NCT05673447 | The Study of Anti-CD19 CAR NK Cells in the Treatment of Relapsed/Refractory Diffuse Large B Cell Lymphoma | unknown | Early Phase 1 | 12 | Changhai HospitalOTHER | 1 | Aug 28, 2023 | clinicaltrials |
| NCT06007989 | Assessing the Relationship Between Hypoxia and the Immune Environment in Myeloma Patients (CHIME)(CHIME) | unknown | — | 10 | The Christie NHS Foundation TrustOTHER | 1 | Aug 23, 2023 | clinicaltrials |
| NCT02471391 | ABT-199 & Ibrutinib in Mantle Cell Lymphoma (AIM)(AIM) | unknown | Phase 2 | 37 | Peter MacCallum Cancer Centre, AustraliaOTHER | 1 | Aug 21, 2023 | clinicaltrials |
| NCT03331731 | A Phase II Study to Determine Pembrolizumab as Frontline Treatment of Patients With Hodgkin Lymphoma(PLIMATH) | unknown | Phase 2 | 27 | Peter MacCallum Cancer Centre, AustraliaOTHER | 2 | Aug 21, 2023 | clinicaltrials |
| NCT05979792 | Clinical Study of CD7 CAR-T Cell Injection in the Treatment of Patients With Relapsed or Refractory CD7-positive Peripheral T Cell Lymphoma | unknown | Early Phase 1 | 35 | Zhao WeiliOTHER | 1 | Aug 21, 2023 | clinicaltrials |
| NCT05990985 | The Efficacy and Safety of the RCMOP Sequential Therapy as a First-line Treatment for Patients With Intermediate-to-high Risk Diffuse Large B-cell Lymphoma Who Had Incomplete Remission. | unknown | N/A | 20 | The First Hospital of Jilin UniversityOTHER | 1 | Aug 18, 2023 | clinicaltrials |
| NCT05995808 | Cyclin D1 as a Prognostic Factor in Multiple Myeloma and Its Association With the Immunological Prognostic Factor PDL1 and Clinical and Biochemical Lab Tests | unknown | N/A | 30 | Sohag UniversityOTHER | 0 | Aug 16, 2023 | clinicaltrials |
| NCT05390528 | A Study Evaluating the Safety, Tolerability, Pharmacokinetic and Efficacy of HLX301(TIGIT×PDL1 Bispecific) in Locally Advanced/Metastatic Solid Tumors or Lymphoma(HLX301) | unknown | Phase 1 / Phase 2 | 30 | Shanghai Henlius BiotechINDUSTRY | 1 | Aug 8, 2023 | clinicaltrials |
| NCT05974085 | XPO-1 in Combination With RCHOP for DH/TH Lymphoma | unknown | Phase 2 | 10 | Zhejiang Cancer HospitalOTHER | 1 | Aug 3, 2023 | clinicaltrials |
| NCT05005299 | Venetoclax in Combination With Non-myeloablative Conditioning Allogeneic Haematopoietic Stem Cell Transplantation(VICTORY) | unknown | Phase 1 | 18 | Melbourne HealthOTHER | 1 | Aug 1, 2023 | clinicaltrials |
| NCT05871684 | A Combination Study of CAR-T Therapy in r/r B-NHL | unknown | Phase 2 | 48 | Ruijin HospitalOTHER | 1 | Aug 1, 2023 | clinicaltrials |
| NCT05967975 | Elastography and Treatment of Lymphoma | unknown | — | 44 | Assiut UniversityOTHER | 0 | Aug 1, 2023 | clinicaltrials |
| NCT05968001 | Obinutuzumab in Chinese Real-world Patients With iNHL | unknown | — | 400 | Affiliated Hospital of Nantong UniversityOTHER | 1 | Aug 1, 2023 | clinicaltrials |
| NCT05887726 | Zanubrutinib Combined With R-CHOP Regimen in the Treatment of Newly Diagnosed DLBCL With High-risk Factors | unknown | Phase 2 | 30 | Liaoning Cancer Hospital & InstituteOTHER | 1 | Jul 27, 2023 | clinicaltrials |
| NCT05964270 | Telemonitoring Among Patients With Multiple Myeloma(ITUMM) | unknown | N/A | 150 | IsalaOTHER | 1 | Jul 27, 2023 | clinicaltrials |
| NCT05020392 | Autologous Cells Derived Anti-CD19 CAR-Engineered T Cells With Concurrent BTK Inhibitor for B Cell Lymphoma | unknown | Phase 3 | 24 | Union Hospital, Tongji Medical College, Huazhong University of Science and TechnologyOTHER | 1 | Jul 25, 2023 | clinicaltrials |
| NCT04143932 | Multiple Myeloma Turkish Prospective Patient Registry(THD-MM-Reg) | unknown | — | 1,000 | Turkish Hematology AssociationOTHER | 1 | Jul 18, 2023 | clinicaltrials |
| NCT05950490 | Construction of Diagnosis and Treatment System for Primary Vitreoretinal Lymphoma | unknown | — | 100 | Peking Union Medical College HospitalOTHER | 1 | Jul 18, 2023 | clinicaltrials |
| NCT02825836 | Phase I/II, FIH, Dose Escalation Trial of TL-895 and Expansion of TL-895 Monotherapy and Combination Therapy With Navtemadlin in Tx-Naïve and R/R CLL/SLL Subjects | unknown | Phase 1 / Phase 2 | 130 | Telios Pharma, Inc.INDUSTRY | 7 | Jul 13, 2023 | clinicaltrials |
| NCT04836871 | Double Filtration Plasmapheresis Combined With Chemotherapy | unknown | Phase 1 | 20 | Fuling ZhouOTHER | 1 | Jul 13, 2023 | clinicaltrials |
| NCT05941156 | Clinical Study of Anti-CD56-CAR-T in the Treatment of Relapsed/Refractory NK/T Cell Lymphoma /NK Cell Leukemia | unknown | Phase 2 | 20 | The Affiliated Hospital of Xuzhou Medical UniversityOTHER | 1 | Jul 12, 2023 | clinicaltrials |
| NCT05940051 | Prospective Clinical Study of ZPR Regimen in Relapsed/Refractory Diffuse Large B-cell Lymphoma | unknown | Phase 2 | 35 | Peng LiuOTHER | 1 | Jul 11, 2023 | clinicaltrials |
| NCT05940064 | Prospective Clinical Study of ZPR Regimen in Elderly Treatment-naive Diffuse Large B-cell Lymphoma | unknown | Phase 2 | 30 | Peng LiuOTHER | 1 | Jul 11, 2023 | clinicaltrials |
| NCT03695744 | Daratumumab in Combination With Bortezomib and Dexamethasone in Newly Diagnosed Transplant Ineligible Multiple Myeloma | unknown | Phase 2 | 27 | Singapore General HospitalOTHER | 1 | Jul 10, 2023 | clinicaltrials |
| NCT04763083 | First in Human Study of NVG-111 in Relapsed/Refractory ROR1+ Malignancies | unknown | Phase 1 | 90 | NovalGen Ltd.INDUSTRY | 1 | Jul 7, 2023 | clinicaltrials |
| NCT05631912 | TRAC Locus-inserted CD19-targeting STAR-T Cell Therapy in r/r B-NHL | unknown | Phase 1 / Phase 2 | 38 | Chinese PLA General HospitalOTHER | 1 | Jul 6, 2023 | clinicaltrials |
| NCT05934045 | Deciphering the Role of Circular RNAs in ALKpositive Anaplastic Large-cell Lymphoma(CIRComa) | unknown | — | 80 | University Hospital, ToulouseOTHER | 1 | Jul 6, 2023 | clinicaltrials |
Data updated 23 days agoSource updated Oct 6, 2023source: clinicaltrials